Compare GEL & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEL | ABSI |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.4B |
| IPO Year | 1996 | 2021 |
| Metric | GEL | ABSI |
|---|---|---|
| Price | $14.15 | $9.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $18.00 | $14.90 |
| AVG Volume (30 Days) | 219.3K | ★ 3.6M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | ★ 5.75% | N/A |
| EPS Growth | N/A | ★ 10.64 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $2,912,770,000.00 | $4,534,000.00 |
| Revenue This Year | $9.79 | $39.03 |
| Revenue Next Year | N/A | $310.91 |
| P/E Ratio | $66.14 | ★ N/A |
| Revenue Growth | ★ 43.60 | N/A |
| 52 Week Low | $13.55 | $2.24 |
| 52 Week High | $18.64 | $12.06 |
| Indicator | GEL | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 43.72 | 48.08 |
| Support Level | $13.65 | $8.15 |
| Resistance Level | $14.61 | $11.73 |
| Average True Range (ATR) | 0.30 | 0.86 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 40.70 | 26.66 |
Genesis Energy LP focuses on the midstream segment of the crude oil and natural gas industry. It offers various services to crude oil and natural gas producers, and industrial and commercial enterprises. The company's reportable segments are: Offshore pipeline transportation, Marine transportation, and Onshore transportation and services. Maximum revenue is generated from the Offshore pipeline transportation segment, which includes the transportation and processing of crude oil and natural gas in the Gulf of America. The Marine transportation segment provides waterborne transportation of petroleum products and crude oil throughout North America; and the Onshore transportation and services segment deals with crude oil logistics, sour gas processing, and sells sulfur byproducts.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.